Long-term cardiovascular risk in the orthotopic liver transplant population

Christopher P. Appleton, R. Todd Hurst, Kwan S Lee, Christina Reuss, Joseph G. Hentz

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In summary, Guckelberger and colleagues add valuable further evidence that aggressive, often premature CV disease is a serious problem in long term OLTx survivors. Large prospective studies with sufficient statistical power need to be organized to assess which patients are at the highest risk for CV events and therefore will benefit form aggressive medical intervention. The author's assertion that there are significant differences in the three gloval CV disease risk stratification algorithms studied is less certain, and the conclusion that PROCAM risk estimates are "required" in the setup of prospective intervention trials is not supported by their data. Since global risk assesment for CV disease entails examination of all available risk factors (16) we suggest that future prospective studies add newer reported risk factors to those previously established including serum high sensitivity C-reactive protein, fibrinogen, homocysteine, lipoprotein a (LPa) and apolipoproteins A1 and B.

Original languageEnglish (US)
Pages (from-to)352-355
Number of pages4
JournalLiver Transplantation
Volume12
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Transplants
Liver
Population
Prospective Studies
Lipoprotein(a)
Apolipoprotein A-I
Apolipoproteins B
Homocysteine
C-Reactive Protein
Fibrinogen
Survivors
Serum

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Long-term cardiovascular risk in the orthotopic liver transplant population. / Appleton, Christopher P.; Hurst, R. Todd; Lee, Kwan S; Reuss, Christina; Hentz, Joseph G.

In: Liver Transplantation, Vol. 12, No. 3, 03.2006, p. 352-355.

Research output: Contribution to journalArticle

Appleton, Christopher P. ; Hurst, R. Todd ; Lee, Kwan S ; Reuss, Christina ; Hentz, Joseph G. / Long-term cardiovascular risk in the orthotopic liver transplant population. In: Liver Transplantation. 2006 ; Vol. 12, No. 3. pp. 352-355.
@article{ec1126cb0e264490964e62c0983ccca5,
title = "Long-term cardiovascular risk in the orthotopic liver transplant population",
abstract = "In summary, Guckelberger and colleagues add valuable further evidence that aggressive, often premature CV disease is a serious problem in long term OLTx survivors. Large prospective studies with sufficient statistical power need to be organized to assess which patients are at the highest risk for CV events and therefore will benefit form aggressive medical intervention. The author's assertion that there are significant differences in the three gloval CV disease risk stratification algorithms studied is less certain, and the conclusion that PROCAM risk estimates are {"}required{"} in the setup of prospective intervention trials is not supported by their data. Since global risk assesment for CV disease entails examination of all available risk factors (16) we suggest that future prospective studies add newer reported risk factors to those previously established including serum high sensitivity C-reactive protein, fibrinogen, homocysteine, lipoprotein a (LPa) and apolipoproteins A1 and B.",
author = "Appleton, {Christopher P.} and Hurst, {R. Todd} and Lee, {Kwan S} and Christina Reuss and Hentz, {Joseph G.}",
year = "2006",
month = "3",
doi = "10.1002/lt.20716",
language = "English (US)",
volume = "12",
pages = "352--355",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Long-term cardiovascular risk in the orthotopic liver transplant population

AU - Appleton, Christopher P.

AU - Hurst, R. Todd

AU - Lee, Kwan S

AU - Reuss, Christina

AU - Hentz, Joseph G.

PY - 2006/3

Y1 - 2006/3

N2 - In summary, Guckelberger and colleagues add valuable further evidence that aggressive, often premature CV disease is a serious problem in long term OLTx survivors. Large prospective studies with sufficient statistical power need to be organized to assess which patients are at the highest risk for CV events and therefore will benefit form aggressive medical intervention. The author's assertion that there are significant differences in the three gloval CV disease risk stratification algorithms studied is less certain, and the conclusion that PROCAM risk estimates are "required" in the setup of prospective intervention trials is not supported by their data. Since global risk assesment for CV disease entails examination of all available risk factors (16) we suggest that future prospective studies add newer reported risk factors to those previously established including serum high sensitivity C-reactive protein, fibrinogen, homocysteine, lipoprotein a (LPa) and apolipoproteins A1 and B.

AB - In summary, Guckelberger and colleagues add valuable further evidence that aggressive, often premature CV disease is a serious problem in long term OLTx survivors. Large prospective studies with sufficient statistical power need to be organized to assess which patients are at the highest risk for CV events and therefore will benefit form aggressive medical intervention. The author's assertion that there are significant differences in the three gloval CV disease risk stratification algorithms studied is less certain, and the conclusion that PROCAM risk estimates are "required" in the setup of prospective intervention trials is not supported by their data. Since global risk assesment for CV disease entails examination of all available risk factors (16) we suggest that future prospective studies add newer reported risk factors to those previously established including serum high sensitivity C-reactive protein, fibrinogen, homocysteine, lipoprotein a (LPa) and apolipoproteins A1 and B.

UR - http://www.scopus.com/inward/record.url?scp=33645313776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645313776&partnerID=8YFLogxK

U2 - 10.1002/lt.20716

DO - 10.1002/lt.20716

M3 - Article

VL - 12

SP - 352

EP - 355

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -